TICKERNERD
Menu
DWTXDWTXHealthcare · Biotechnology

DWTX Stock Forecast: Dogwood Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$1.69
−1.74% on the day

The 2 Wall Street analysts covering Dogwood Therapeutics, Inc. hold a median 12-month price target of $15 — +787.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 19 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$57.4M
Ticker Nerd rank
37 / 100
Median analyst target
$15
Analysts covering
2
Revenue$0.0
Operating income−$4.9M
Net income−$11.5M
Free cash flow−$3.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−12.9%
1M
−21.0%
YTD
−59.4%
1Y
−64.9%
From 52W high
−78.6%
From 52W low
+26.1%
$1.34
$7.91
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DWTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Dogwood Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
37 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
91
Size
81
Quality
68
Growth
57
Value
35
Volatility
30
Revisions
27
Issuance
25
Momentum
7

Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (7): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DWTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DWTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Oct 25Jan 26Apr 26Jul 26DWTXHigh $15Median $15Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $12Median $15High $15

The green dot is the last close — the median target sits +787.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 May 2026HC Wainwright & Co.ReiteratesBuy$12
27 Apr 2026HC Wainwright & Co.ReiteratesBuy—
20 Feb 2026HC Wainwright & Co.ReiteratesBuy—
30 Jan 2026HC Wainwright & Co.ReiteratesBuy—
30 Sept 2025HC Wainwright & Co.MaintainsBuy—
23 Apr 2025HC Wainwright & Co.UpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DWTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

DWTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Dogwood Therapeutics, Inc. returned −64.9% against +16.3% for the S&P 500, dividends included.

DWTX vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140Oct 25Jan 26Apr 26Jul 26DWTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DWTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Dogwood Therapeutics, Inc. (DWTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.9×

Cheaper than 71% of US stocks

Price / sales
—
Price / book
0.8×

Cheaper than 77% of US stocks

EV / EBITDA
−1.6×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−47.8%

Higher than 22% of US stocks

Return on assets
−20.8%

Higher than 19% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Dogwood Therapeutics, Inc. (DWTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Dogwood Therapeutics, Inc. has a market value of $57.4M and an enterprise value of $47.6M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$36.0M.

  • Diluted earnings per share, trailing twelve months: $−8.95.

  • Free cash flow in the twelve months to 30 June 2026: −$15.1M.

  • Shares outstanding: 33.6M.

  • Trailing P/E: 0.9×; forward P/E: −0.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Dogwood Therapeutics, Inc. employs 8 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

DWTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DWTXDogwood Therapeutics, Inc.$57.4M
37
SERSerina Therapeutics, Inc.$57.2M
19
IMAImageneBio, Inc.$57.8M
30
HRTXHeron Therapeutics, Inc.$58.8M
44
EDSAEdesa Biotech, Inc.$55.9M
53
HYPDHyperion DeFi, Inc.$59.4M
39
EXOZeXoZymes, Inc.$59.7M
12

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Dogwood Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DWTX news & analysis

Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial

GlobeNewsWire · 14 Sept 2026positive

Dogwood Therapeutics announced completion of patient enrollment in its ongoing Halneuron Phase 2b Chemotherapy Induced Neuropathic Pain trial, with 239 patients enrolled, meeting the upper end of the planned enrollment target range. Topline data are expected in November 2026.

Why it matters — A DWTX watcher would care because completion of enrollment at the target level moves the Halneuron Phase 2b CINP trial a step closer to topline results, a key clinical milestone for the company's pain program.

Dogwood Therapeutics, Inc. (DWTX) Discusses Halneuron and Pipeline Advances for Chemotherapy-Induced Neuropathic Pain Transcript

Seeking Alpha · 2 Sept 2026neutral

Dogwood Therapeutics, Inc. (DWTX) discussed its Halneuron program and pipeline advances for chemotherapy-induced neuropathic pain during a transcript of the discussion. The item covers the company's progress on this treatment candidate.

Why it matters — A DWTX watcher would care because the discussion provides an update on the company's Halneuron pipeline for chemotherapy-induced neuropathic pain.

Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment

MarketBeat · 1 Sept 2026positive

Dogwood Therapeutics announced that its Phase 2b study of Halneuron, an investigational treatment for chemotherapy-induced neuropathic pain, has enrolled more than 230 patients. The company expects to report top-line data from the trial later this fall.

Why it matters — The upcoming Phase 2b top-line data readout for Halneuron represents a significant clinical milestone for Dogwood Therapeutics that could determine the treatment's future development prospects.

Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026

GlobeNewsWire · 17 Aug 2026neutral

Dogwood Therapeutics announced it will host a virtual key opinion leader (KOL) event on September 1, 2026, to discuss Halneuron for the treatment of chemotherapy-induced neuropathic pain (CINP). The event will feature Dr. J. Mark Joyce, Iain D. Dukes, and Dr. Jerry Evarts alongside company management to cover the unmet need and current treatment landscape for CINP.

Why it matters — The KOL event gives DWTX watchers an opportunity to hear expert perspectives on the unmet need and treatment landscape for CINP, providing additional context around the company's Halneuron development program.

Dogwood Therapeutics Announces Second Quarter 2026 Financial Results

GlobeNewsWire · 13 Aug 2026neutral

Dogwood Therapeutics reported its second quarter 2026 financial results. The company noted that its Halneuron Phase 2b trial in Chemotherapy Induced Neuropathy is on track for top-line results in fall 2026, with 217 patients enrolled.

Why it matters — A DWTX watcher would care because the upcoming Phase 2b readout for Halneuron represents a key clinical milestone for the pipeline.

FAQ

Frequently asked questions about DWTX stock

What is the DWTX stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Dogwood Therapeutics, Inc. have a median 12-month price target of $15, with estimates ranging from $12 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DWTX stock a buy right now?

Of the 2 analysts covering Dogwood Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Dogwood Therapeutics, Inc. 37 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DWTX?

As at 19 Sept 2026, Dogwood Therapeutics, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).

Will DWTX stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +787.6% from the last close, and Ticker Nerd's factor model ranks Dogwood Therapeutics, Inc. 37 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DWTX stock forecast for 2030?

No analyst covering Dogwood Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DWTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $15 over the next 12 months.

How has DWTX stock performed over the past year?

Dogwood Therapeutics, Inc. returned -64.9% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Dogwood Therapeutics, Inc. do?

Dogwood Therapeutics Inc. is a development-stage biopharmaceutical company focused on advancing medicines for pain and neuropathy.

What is the latest news on DWTX?

The most recent item we track (GlobeNewsWire, 14 Sept 2026): "Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial". Dogwood Therapeutics announced completion of patient enrollment in its ongoing Halneuron Phase 2b Chemotherapy Induced Neuropathic Pain trial, with 239 patients enrolled, meeting the upper end of the planned enrollment target range. Topline data are expected in November 2026.

Company

About Dogwood Therapeutics, Inc.

Dogwood Therapeutics Inc. is a development-stage biopharmaceutical company focused on advancing medicines for pain and neuropathy. The company’s current pipeline centers on non-opioid therapies, including Halneuron®, a voltage-gated sodium channel modulator being developed for neuropathic pain and other pain conditions, and SP16, a cell-signaling-based program aimed at neuropathy and nerve damage. Dogwood Therapeutics also works on antiviral combination therapies designed for illnesses linked to virus-triggered immune responses, including pain and fatigue-related disorders. Based in Alpharetta, Georgia, Dogwood Therapeutics operates as a single-segment company with an emphasis on clinical development, preclinical research, and targeted treatment approaches for cancer-related pain, neuropathic disorders, and related conditions.

CEO Mr. Gregory Duncan · 8 employees · United States · https://dwtx.com